TY - JOUR
T1 - Hypothalamic-Pituitary Outcome after Treatment for Childhood Craniopharyngioma
AU - Van Schaik, Jiska
AU - Hoving, Eelco W.
AU - Müller, Hermann L.
AU - Van Santen, Hanneke M.
N1 - Funding Information:
H.L.M. was funded by grants (DKS2014.13) of the German Childhood Cancer Foundation, Bonn, Germany.
Publisher Copyright:
© 2021 S. Karger AG. All rights reserved.
PY - 2021/11/1
Y1 - 2021/11/1
N2 - Although childhood-onset craniopharyngioma is a low-grade intracranial tumor with excellent prognosis in terms of overall survival, survivors may suffer from devastating consequences caused by hypothalamic damage. Disease- or treatment-related hypothalamic damage leads to disturbed hunger-satiety and thirst feelings, decreased energy expenditure, behavioral problems, disturbances of circadian rhythm, temperature dysregulation, and pituitary dysfunction. These children are at great risk for developing the metabolic syndrome and comorbidities leading to premature mortality. In this chapter, we shall discuss hypothalamic-pituitary morbidity and outcome of childhood-onset craniopharyngioma patients and future perspectives for improvement.
AB - Although childhood-onset craniopharyngioma is a low-grade intracranial tumor with excellent prognosis in terms of overall survival, survivors may suffer from devastating consequences caused by hypothalamic damage. Disease- or treatment-related hypothalamic damage leads to disturbed hunger-satiety and thirst feelings, decreased energy expenditure, behavioral problems, disturbances of circadian rhythm, temperature dysregulation, and pituitary dysfunction. These children are at great risk for developing the metabolic syndrome and comorbidities leading to premature mortality. In this chapter, we shall discuss hypothalamic-pituitary morbidity and outcome of childhood-onset craniopharyngioma patients and future perspectives for improvement.
UR - http://www.scopus.com/inward/record.url?scp=85107504694&partnerID=8YFLogxK
U2 - 10.1159/000515318
DO - 10.1159/000515318
M3 - Article
C2 - 33965963
SN - 0301-3073
VL - 54
SP - 47
EP - 57
JO - Frontiers of hormone research
JF - Frontiers of hormone research
ER -